<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05011851</url>
  </required_header>
  <id_info>
    <org_study_id>NEU-2591-AS-001</org_study_id>
    <nct_id>NCT05011851</nct_id>
  </id_info>
  <brief_title>An Open-Label Study of the Safety, Tolerability, and Pharmacokinetics of Oral NNZ-2591 in Angelman Syndrome</brief_title>
  <acronym>AS-001</acronym>
  <official_title>An Open-Label Study of the Safety, Tolerability, and Pharmacokinetics of Oral NNZ-2591 in Angelman Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Neuren Pharmaceuticals Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Neuren Pharmaceuticals Limited</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A study of the safety, tolerability and pharmacokinetics of NNZ-2591 and measures of efficacy&#xD;
      in children and adolescents with Angelman syndrome&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary purpose of this study is to investigate the safety, tolerability and&#xD;
      pharmacokinetics of treatment with NNZ-2591 oral solution in children and adolescents with&#xD;
      Angelman syndrome. The secondary purpose is to investigate measures of efficacy. Subjects&#xD;
      will receive treatment of orally administered NNZ-2591 oral solution (50 mg/mL) at&#xD;
      weight-banded doses for a total of 13 weeks&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 1, 2021</start_date>
  <completion_date type="Anticipated">September 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and Tolerability</measure>
    <time_frame>13 weeks</time_frame>
    <description>To examine the incidence, severity and frequency of adverse events (AEs), including serious adverse events (SAEs) during treatment with NNZ-2591.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetic - Measurement of Cmax</measure>
    <time_frame>13 weeks</time_frame>
    <description>Maximum observed concentration (Cmax) of NNZ-2591</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetic - Measurement of AUC</measure>
    <time_frame>13 weeks</time_frame>
    <description>Area under the concentration-time curve of NNZ-2591</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetic - Measurement of time to Cmax</measure>
    <time_frame>13 weeks</time_frame>
    <description>Time to Cmax of NNZ-2591</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetic - Measurement of t1/2</measure>
    <time_frame>13 weeks</time_frame>
    <description>Apparent terminal elimination half-life of NNZ-2591</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Exploratory efficacy measurement</measure>
    <time_frame>13 weeks</time_frame>
    <description>Assessed by Angelman syndrome-specific Clinical Global Impression Scale-Overall Improvement (CGI-I)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Exploratory efficacy measurement</measure>
    <time_frame>13 weeks</time_frame>
    <description>Assessed by Caregiver Impression of Improvement</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Exploratory efficacy measurement</measure>
    <time_frame>13 weeks</time_frame>
    <description>Assessed by Angelman syndrome-specific Clinical Global Impression Scales-Domain Improvement</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Exploratory efficacy measurement</measure>
    <time_frame>13 weeks</time_frame>
    <description>Assessed by Angelman syndrome-specific Clinical Global Impression Scale-Severity (CGI-S)-Overall and Domain</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Exploratory efficacy measurement</measure>
    <time_frame>13 weeks</time_frame>
    <description>Assessed by Angelman syndrome Clinician Domain Specific Rating Scale (AS-DSRS)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Exploratory efficacy measurement</measure>
    <time_frame>13 weeks</time_frame>
    <description>Assessed by Caregiver Top 3 Concerns Likert Scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Exploratory efficacy measurement</measure>
    <time_frame>13 weeks</time_frame>
    <description>Assessed by MacArthur-Bates Communicative Development Inventory (MB-CDI)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Exploratory efficacy measurement</measure>
    <time_frame>13 weeks</time_frame>
    <description>Assessed by Observer-Reported Communication Ability (ORCA)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Exploratory efficacy measurement</measure>
    <time_frame>13 weeks</time_frame>
    <description>Assessed by Aberrant Behavior Checklist-2 (ABC-2)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Exploratory efficacy measurement</measure>
    <time_frame>13 weeks</time_frame>
    <description>Assessed by Child Sleep Habits Questionnaire (CSHQ)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Exploratory efficacy measurement</measure>
    <time_frame>13 weeks</time_frame>
    <description>Assessed by Gastrointestinal Health Questionnaire (GIHQ)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Exploratory efficacy measurement</measure>
    <time_frame>13 weeks</time_frame>
    <description>Assessed by Vineland Adaptive Behavior Scales-3, Interview version</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Exploratory efficacy measurement</measure>
    <time_frame>13 weeks</time_frame>
    <description>Assessed by Bayley Scales of Infant Development-4, Vineland Motor subscales</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Exploratory efficacy measurement</measure>
    <time_frame>13 weeks</time_frame>
    <description>Caregiver Diaries</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Exploratory efficacy measurement</measure>
    <time_frame>13 weeks</time_frame>
    <description>Assessed by Quality of Life Inventory-Disability (QI-Disability)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Exploratory efficacy measurement</measure>
    <time_frame>13 weeks</time_frame>
    <description>Assessed by Impact of Childhood Neurological Disability (ICND)-Overall quality of life rating</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Angelman Syndrome</condition>
  <arm_group>
    <arm_group_label>NNZ-2591</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>NNZ-2591 oral solution (50mg/mL) to be administered twice daily at a weight-banded dose for 13 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NNZ-2591</intervention_name>
    <description>NNZ-2591 oral solution (50mg/mL) to be administered twice daily at a weight-banded dose for 13 weeks.</description>
    <arm_group_label>NNZ-2591</arm_group_label>
    <other_name>Cyclo-L-Glycyl-L-2-Allylproline</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Clinical diagnosis of AS with a documented disease-causing genetic etiology known to&#xD;
             impact maternally derived UBE3A expression in brain.&#xD;
&#xD;
          2. Males or females aged 3-17 years&#xD;
&#xD;
          3. Subjects with a Clinical Global Impression - Severity (CGI-S) score of 3 or greater at&#xD;
             the Screening visit.&#xD;
&#xD;
          4. Each subject must be able to swallow the study medication provided as a liquid&#xD;
             solution.&#xD;
&#xD;
          5. Caregiver(s) must have sufficient English language skills.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Mosaicism for disease-causing mutation.&#xD;
&#xD;
          2. Clinically significant abnormalities in safety laboratory tests at Screening.&#xD;
&#xD;
          3. Abnormal QTcF interval or prolongation at Screening.&#xD;
&#xD;
          4. Any other clinically significant finding (as determined by the Investigator) on ECG at&#xD;
             the Screening visit.&#xD;
&#xD;
          5. Excluded concomitant treatments.&#xD;
&#xD;
          6. Actively undergoing regression or loss of skills.&#xD;
&#xD;
          7. Unstable seizure profile.&#xD;
&#xD;
          8. Current clinically significant (as determined by the Investigator) cardiovascular,&#xD;
             renal, hepatic, gastrointestinal, respiratory, endocrine disease, or clinically&#xD;
             significant organ impairment.&#xD;
&#xD;
          9. Current clinically significant (as determined by the Investigator) hypo or&#xD;
             hyperthyroidism.&#xD;
&#xD;
         10. Type 1 or Type 2 diabetes mellitus requiring insulin (whether well controlled or&#xD;
             uncontrolled), or uncontrolled Type 1 or Type 2 diabetes.&#xD;
&#xD;
         11. Has planned surgery during the study.&#xD;
&#xD;
         12. History of, or current, cerebrovascular disease or brain trauma.&#xD;
&#xD;
         13. History of, or current catatonia or catatonia-like symptoms.&#xD;
&#xD;
         14. History of, or current, malignancy.&#xD;
&#xD;
         15. Current major or persistent depressive disorder (including bipolar depression).&#xD;
&#xD;
         16. Significant, uncorrected visual or uncorrected hearing impairment.&#xD;
&#xD;
         17. Allergy to strawberry.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>3 Years</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>James Shaw</last_name>
    <role>Study Director</role>
    <affiliation>Neuren Pharmaceuticals</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Patrick Kim</last_name>
    <phone>+61 2 9171 3267</phone>
    <email>Patrick.Kim@novotech-cro.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Sydney Children's Hospital</name>
      <address>
        <city>Randwick</city>
        <state>New South Wales</state>
        <zip>2031</zip>
        <country>Australia</country>
      </address>
    </facility>
    <contact>
      <last_name>James Shaw</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre for Clinical Trials in Rare Neurodevelopmental Disorders at Children's Health Queensland Hospital and Health Service</name>
      <address>
        <city>South Brisbane</city>
        <state>Queensland</state>
        <zip>4101</zip>
        <country>Australia</country>
      </address>
    </facility>
    <contact>
      <last_name>James Shaw</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Austin Health</name>
      <address>
        <city>Heidelberg</city>
        <state>Victoria</state>
        <zip>3084</zip>
        <country>Australia</country>
      </address>
    </facility>
    <contact>
      <last_name>James Shaw</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Australia</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>August 5, 2021</study_first_submitted>
  <study_first_submitted_qc>August 13, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 18, 2021</study_first_posted>
  <last_update_submitted>August 26, 2021</last_update_submitted>
  <last_update_submitted_qc>August 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Angelman Syndrome</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Angelman Syndrome</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

